Active specific immunotherapy with supportive measures in the treatment of advanced palliatively nephrectomised renal adenocarcinoma. A controlled clinical study.
D000230:Adenocarcinoma / Q000628:therapy*; D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000368:Aged; D002986:Clinical Trials as Topic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007117:Immunization, Secondary / Q000009:adverse effects; D007680:Kidney Neoplasms / Q000401:mortality / Q000628:therapy*; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy / Q000401:mortality; D010166:Palliative Care; D011182:Postoperative Care; D011300:Preoperative Care; D011379:Prognosis; D011859:Radiography; D014374:Tuberculin Test
D000276:Adjuvants, Immunologic